Factory Building News
Factory Building News
ByArticle Source Logo
Pharma Manufacturing – <a href="https://industrialepoxy.com.au/2026/07/18/flooring-tips-for-cannabis-growing-facilities-cannabis-industry-journal/” title=”Flooring Tips for Cannabis Growing Facilities – Cannabis Industry Journal”>Facilities•07-18-2026July 18, 2026•2 min

MilliporeSigma, the U.S. and Canada life science business of Merck KGaA headquartered in Darmstadt, Germany, has opened a €25 million ($29 million) BioReliance testing facility in Darmstadt, expanding its European capabilities for commercial drug substance and drug product release testing

The 2,000-square-meter facility will provide commercial release testing and Good Manufacturing Practice (GMP)-compliant stability studies for biologics, including monoclonal antibodies and cell therapies. According to the company, the site expands its BioReliance testing network and supports customers from drug development through commercial manufacturing

Located near major clinical trial hubs in Germany, France, Spain, the Netherlands, Belgium and Italy, the facility is intended to help biopharmaceutical companies meet European requirements for in-region drug product release testing and commercialization, according to the announcement. MilliporeSigma said staffing at the site will continue to expand in response to customer demand

The facility also becomes part of the company’s global BioReliance testing network, which provides analytical characterization, biosafety testing, and quality control services across multiple regions

Paolo Carli, head of advanced solutions for the life science business of Merck KGaA, said in a statement that locating testing capabilities closer to European drug developers is intended to support commercialization of biologics and other advanced therapies

The Darmstadt facility is one of several investments the company has made to grow its global contract testing footprint. In 2024, the company opened a €290 million ($286 million) biosafety testing facility in Rockville, Maryland, and expanded biosafety testing capacity across its Glasgow and Stirling sites in Scotland through a €22 million investment

More recently, the company partnered with ProtaGene, a protein characterization company headquartered in Heilbronn, Germany, to provide an integrated testing platform that combines protein characterization services with GMP testing infrastructure

According to the companies, the collaboration is designed to support biologics developers from early-stage characterization through commercial release testing while streamlining project management and regulatory support

Recent Comments
Pharma Manufacturing – Facilities•Jul 18, 2026•2 minPlant Service
Plant Service•Jul 17, 2026•2 minBattery News
Battery News•Jul 17, 2026•2 minPharma Manufacturing – Facilities•Jul 17, 2026•4 minPharma Manufacturing – Facilities•Jul 17, 2026•2 minPharma Manufacturing – Facilities•Jul 17, 2026•2 minPlant Service•Jul 17, 2026•3 minBattery News•Jul 16, 2026•2 minPharma Manufacturing – Facilities•Jul 16, 2026•4 minPharma Manufacturing – Facilities•Jul 16, 2026•2 minPlant Service•Jul 15, 2026•3 minPlant Service•Jul 15, 2026•2 minPlant
Plant•Jul 15, 2026•6 minBattery News•Jul 14, 2026•2 minPharma Manufacturing – Facilities•Jul 14, 2026•2 minPlant Service•Jul 13, 2026•3 minBattery News•Jul 11, 2026•1 minPharma Manufacturing – Facilities•Jul 11, 2026•1 minPharma Manufacturing – Facilities•Jul 11, 2026•2 minProperty Forum
Property Forum•Jul 10, 2026•2 min

Leave a Reply

Your email address will not be published. Required fields are marked *